Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 292 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Why do non-smokers face delays in getting a lung cancer diagnosis? November 25, 2022 High Frequency of Germline ATM Variants in CLL November 11, 2022 FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection October 2, 2025 Many Older Adults Screened Unnecessarily for Common Cancers August 27, 2020 Load more HOT NEWS News digest – sponge on a string, junk food watershed, prostate... Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with... Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is... EMA Recommends Granting a Conditional Marketing Authorisation for Repotrectinib
